Physician profile
Rama Poola
NPI 1932362241
$4,418.97
in general payments reported to CMS, 2019-2025
32 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $47.24 · 2021: $44.73 · 2022: $146 · 2023: $1,103 · 2024: $1,448 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,997.62 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $398.25 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $379.90 | 2023-2025 | |
| Amgen INC. | $340.07 | 2022-2025 | Repatha, Evenity, Repatha |
| Abbott Laboratories | $303.25 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Freestyle Insulinx |
| Abbvie INC. | $266.55 | 2023-2025 | |
| Corcept Therapeutics | $228.99 | 2019-2025 | Korlym |
| Medtronic, INC. | $207.11 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $200.01 | 2022-2025 | Omnipod, Omnipod |
| Radius Health, INC. | $182.85 | 2023-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $169.56 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $111.74 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $109.13 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.69 | 2022-2024 | Jardiance, Synjardy |
| Tandem Diabetes Care, INC. | $92.00 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $88.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $84.40 | 2022-2023 | |
| Amphastar Pharmaceuticals, INC. | $77.28 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $68.69 | 2022-2025 | |
| Sandoz INC. | $63.18 | 2025 | Hyrimoz |
| Mannkind Corporation | $62.60 | 2023-2024 | Afrezza |
| Medtronic Minimed, INC. | $58.26 | 2019 | |
| Sequel Med Tech, LLC | $43.68 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $42.99 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $40.30 | 2025 | |
| Madrigal Pharmaceuticals | $34.83 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals Lp | $33.56 | 2021-2024 | Farxiga |
| Horizon Therapeutics Plc | $31.78 | 2023 | Tepezza |
| Esperion Therapeutics, INC. | $25.10 | 2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $22.81 | 2024 | Unithroid |
| Dexcom, INC. | $16.48 | 2020 | |
| Cequr Corporation | $12.25 | 2023-2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Poola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.